Form 4: STERIS CEO Daniel Carestio Receives Equity Grant

STERIS plc President and CEO Daniel A. Carestio acquired 23,736 ordinary shares and 82,740 stock options in a recent equity compensation filing.

Summary

• President and CEO Daniel A. Carestio was granted 23,736 ordinary shares and 82,740 employee stock options on June 2, 2026.
• The stock options have an exercise price of $230.74 and expire on June 2, 2036.
• 995 shares were withheld to satisfy tax obligations related to the vesting of restricted shares.
• Following these transactions, the CEO holds 72,583 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of executive interests with long-term shareholder value through significant equity and option grants.
• The CEO maintains a substantial direct ownership stake of 72,583 shares.

Negatives

• The transaction involves the withholding of 995 shares for tax purposes, which is a standard but routine reduction in total holdings.

Risks

• The value of the granted options is dependent on the future market performance of STERIS shares exceeding the $230.74 exercise price.

Future Outlook

The equity grants are subject to multi-year vesting schedules, with restricted shares vesting through 2029 and options becoming exercisable in annual tranches through 2030.

Management Comments

• The filing reflects standard executive compensation practices and does not contain qualitative management commentary.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive compensation. Large equity grants to CEOs in the medical technology sector are standard practice to ensure long-term retention and performance alignment.

Comparison to Industry Standards

• The use of multi-year vesting schedules for both restricted stock and options is consistent with standard corporate governance practices for S&P 500 companies.
• The tax withholding mechanism is a standard industry practice for settling tax liabilities upon the vesting of equity awards.

Stakeholder Impact

• Shareholders should view this as a standard alignment of executive incentives with company performance.

Next Steps

• Vesting of restricted shares on June 3, 2026.
• Vesting of restricted shares on June 4, 2026.
• First tranche of options becomes exercisable on June 2, 2027.

Key Dates

Keywords

STERIS, STE, Insider Trading, Executive Compensation, Form 4, Daniel Carestio